| Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction A Segovia-Zafra, DE Di Zeo-Sánchez, C López-Gómez, Z Pérez-Valdés, ... Acta Pharmaceutica Sinica B 11 (12), 3685-3726, 2021 | 34 | 2021 |
| Modeling drug-induced liver injury: current status and future prospects DE Di Zeo-Sánchez, A Segovia-Zafra, G Matilla-Cabello, ... Expert Opinion on Drug Metabolism & Toxicology 18 (9), 555-573, 2022 | 11 | 2022 |
| Recreational drugs and the risk of hepatocellular carcinoma JM Pinazo-Bandera, M García-Cortés, A Segovia-Zafra, MI Lucena, ... Cancers 14 (21), 5395, 2022 | 5 | 2022 |
| Critical review of gaps in the diagnosis and management of drug-induced liver injury associated with severe cutaneous adverse reactions M Villanueva-Paz, H Niu, A Segovia-Zafra, I Medina-Caliz, ... Journal of Clinical Medicine 10 (22), 5317, 2021 | 3 | 2021 |
| FRI-324 Advancing in drug-induced liver injury models development: high content screening in cell-based models derived from skin tissues A Segovia-Zafra, M Villanueva, J Posligua-Garcia, N Montenegro-Navarro, ... Journal of Hepatology 80, S107, 2024 | | 2024 |
| Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network A Segovia-Zafra, M Villanueva-Paz, AS Serras, G Matilla-Cabello, ... Journal of Hepatology, 2024 | | 2024 |
| Immunophenotyping to improve the mechanistic understanding of idiosyncratic drug-induced liver injury: clinical implications and future directions A Cueto-Sánchez, DE Di Zeo-Sánchez, A Segovia-Zafra, ... Exploration of Digestive Diseases 2 (2), 56-76, 2023 | | 2023 |
